The global newborn screening market size valued USD 838 million in 2020 and expected to reach USD 1666.2 million by 2027, at a CAGR of 7.9% during the forecast period 2021 to 2027. Newborn screening is the practice where every newborn baby is tested for certain potentially fatal disorders. As newborns are more liable to infections, newborn screening helps in early diagnosis and proper treatment which can make the difference between lifelong impairment and healthy development. Newborn screening consists of a blood test, hearing screening, and screening for critical congenital heart defects. The screening is done within few days of birth. These screening programs are generally run by state or national governing bodies. In this program, various initiatives have been taken by the Japan’s Society of Obstetrics and Gynecology (JSOG), UK (PEACH), and U.S. Department of Health and Human Services Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC). WHO recommended the newborn screening program in order to safeguard the health of children all over the world. Newborn screening not only saves lives but can also improve the health of the children. The World Health Organization has stated that over 270,000 babies globally die of congenital disorders. In 2010, the WHO has taken a step in order to resolve the neonatal deaths by developing strong surveillance systems. It is reported that more than 2.8 million babies die within the first month due to improper care and screening of the babies. In order to prevent these deaths WHO, Healthy Newborn Network, etc., has taken efforts to bring awareness by educating the parents about the neonatal disorders and the process of safeguarding the health of children.